Your fact-checks will appear here
Ivermectin not approved for COVID-19 treatment
Ivermectin dosing in humans is disease-specific and weight‑based: standard microgram-per-kilogram regimens range from about 150–200 µg/kg for onchocerciasis, strongyloidiasis and enterobiasis, to 400 ...
Ivermectin dosing is weight‑based, typically calculated in micrograms per kilogram and most often given as a single oral dose; common regimens for human parasitic infections fall between about 150 and...
Veterinary ivermectin products commonly come at far higher concentrations and in different delivery forms than human tablets, which raises real risks of overdose, neurotoxicity and other severe advers...
Two oral human ivermectin tablet products carry FDA-approved parasitic indications with weight‑based single‑dose regimens: marketed Stromectol/ivermectin tablets (designed to provide ~200 mcg/kg for s...
Health agencies recommend vaccination, nonpharmaceutical measures (masking, ventilation, testing and isolation), and timely use of authorized or guideline-recommended medical therapies—antivirals, sel...
Preclinical literature shows repeated, drug‑level interactions between ivermectin and multiple chemotherapy or targeted agents—mostly beneficial pharmacodynamic synergies (enhanced tumor cell kill, re...
Human safety data for subcutaneous (SC) or intramuscular (IM) ivermectin intended for injection are extremely limited: a handful of case reports and small pharmacokinetic observations describe compass...
Randomized trials testing ivermectin above 400 µg/kg do exist — most notably the COVER dose‑finding trial (600 and 1200 µg/kg arms), the ACTIV‑6 platform trial with a 600 µg/kg‑per‑day arm, and at lea...
Existing clinical evidence that ivermectin causes liver enzyme elevations in humans is limited but real: randomized/tolerability trials and pharmacovigilance databases document transient aminotransfer...
Randomized and observational studies have tested five‑day ivermectin regimens almost exclusively in the context of COVID‑19, producing a patchwork of contradictory results: small trials from Banglades...
Case series, pharmacovigilance data and isolated case reports describe ivermectin‑associated hepatic injury ranging from asymptomatic transaminase elevations to fulminant hepatitis; most published sig...
Animal formulations of ivermectin have been repeatedly linked to gastrointestinal symptoms, rapid-onset neurotoxicity (including confusion, loss of coordination, seizures, coma) and at least one repor...
Veterinary ivermectin products are manufactured in different concentrations and delivery vehicles than human-approved ivermectin and are designed for species-appropriate dosing and routes, not human u...
Ivermectin is an effective, evidence-based antiparasitic for specific human infections — notably onchocerciasis and strongyloidiasis — when used at approved doses under medical supervision . It is not...
The supplied reporting does not include any contemporary news or statements documenting how President Trump or White House officials reacted to Dr. Sean Conley’s resignation; available items discuss C...
Clinical trials of ivermectin for COVID‑19 range from small, early randomized studies to large community and hospital trials and multiple systematic reviews; results are mixed, with some meta-analyses...
N‑acetylcysteine (NAC) has biological plausibility to blunt spike-protein–mediated inflammation and to help symptoms of long COVID through antioxidant, anti‑inflammatory and disulfide‑breaking actions...
Ivermectin–used widely as an antiparasitic and explored as a repurposed drug–is associated with renal findings only rarely and usually mildly (transient proteinuria or minor tubular markers), and larg...
Human prescription ivermectin is supplied as regulated, weight‑based oral tablets or topical formulations at low, controlled strengths for single‑dose or short‑course use (typically ~0.15–0.20 mg/kg f...
Formulating ivermectin with solubility enhancers such as polyvinylpyrrolidone (PVP) or arabinogalactan (AG) reliably increases apparent solubility and bioavailability and can permit lower effective do...